Omeros Corp Maintains 'Buy' Rating with $36 Price Target: D. Boral Capital.

Omeros (OMER) maintained a 'Buy' rating by D. Boral Capital, with a price target of $36.00. The analyst has kept the rating unchanged. Omeros is a biopharmaceutical company focusing on immunologic disorders, including complement-mediated diseases, cancers, and addictive disorders. The average target price for Omeros is $30.00, with an upside of 628.16% from the current price.

Omeros Corporation (OMER) reported mixed financial results for Q2 2025, with a net loss of $0.43 per share, beating the forecasted loss of $0.46. The company's stock dipped by 0.7% in aftermarket trading, closing at $4.24. Despite the positive earnings surprise, the stock's decline can be attributed to ongoing regulatory challenges and concerns about profitability.

Key Takeaways:
- Earnings Beat: Omeros reported a Q2 2025 EPS of -$0.43, beating the forecast of -$0.46 by $0.03.
- Debt Reduction: The company reduced the outstanding principal on 2026 notes from $98 million to $17 million and eliminated a mandatory prepayment on its term loan.
- Regulatory Hurdles: The narsoplimab BLA resubmission's PDUFA date has been extended to December 2025.
- Financial Stability: Omeros anticipates lower operating expenses in Q3 2025 and projects interest expenses around $9.2 million.

Market Reaction:
Following the earnings announcement, Omeros' stock fell by 0.7% in aftermarket trading, closing at $4.24. The stock has shown significant volatility, with a 53.5% decline over the past six months, though it has recently rebounded with a 13% gain in the past week. The stock remains within its 52-week range of $2.95 to $13.6, with a beta of 2.26 indicating higher volatility than the broader market.

Analyst Rating:
Omeros maintained a 'Buy' rating by D. Boral Capital, with a price target of $36.00. The analyst has kept the rating unchanged, citing the company's potential for growth and the positive outlook for its pipeline.

Outlook:
Omeros is actively preparing for the launch of narsoplimab, targeting 175 transplant centers nationwide. The company is also exploring potential asset acquisitions or licensing deals to bolster its financial position and cover operational costs. However, ongoing regulatory hurdles and potential macroeconomic pressures pose significant risks.

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-omeros-beats-q2-2025-eps-forecast-stock-dips-93CH-4194131